Consensus AbbVie Inc.

Equities

ABBV

US00287Y1091

Real-time Estimate Cboe BZX 10:48:49 2024-06-20 EDT 5-day change 1st Jan Change
171.4 USD +0.03% Intraday chart for AbbVie Inc. +2.82% +10.51%

Evolution of the average Target Price on AbbVie Inc.

Price target over the last 5 years

History of analyst recommendation changes

692baf7b50fd585b85eb81.leQaWJN3dhiUn-29B_c2Nyj8D6DMaIK1mNubUtA6Uh0.2NNJF6Q7N1fW5ovHUrlFBHiuVY2DAeuNyarIGrZlMUT_sW8e4jtPftj9qA~68b615f978b163d25178051632649b66
Piper Sandler Adjusts Price Target on AbbVie to $190 From $185 MT
AbbVie Says Investors Should Sit Out Tutanota Mini-Tender Offer MT
HSBC Upgrades AbbVie to Buy From Hold, Adjusts Price Target to $185 From $161 MT
ANALYST RECOMMENDATIONS : Abbvie, Air Products, Applied Materials, KLA Corporation, UnitedHealth... Our Logo
Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target MT
ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta... Our Logo
Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190 MT
BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating MT
Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196 MT
Barclays Adjusts Price Target on AbbVie to $187 From $195 MT
Deutsche Bank Raises AbbVie's Price Target to $175 Form $170 MT
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating MT
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing MT
Abbvie Insider Sold Shares Worth $10,539,508, According to a Recent SEC Filing MT
ANALYST RECOMMENDATIONS : Abbvie, Align Technology; Ulta Beauty, United Airlines, Currys... Our Logo
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox... Our Logo
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating MT
UBS Adjusts Price Target on AbbVie to $172 from $165, Maintains Neutral Rating MT
Truist Adjusts Price Target on AbbVie to $195 From $180, Maintains Buy Rating MT
Piper Sandler Adjusts Price Target on AbbVie to $185 From $180, Maintains Overweight Rating MT
Morningstar Upgrades AbbVie to Hold From Sell, Increases Price Target to $168 From $137 MT
Wells Fargo Adjusts Price Target on AbbVie to $200 From $180, Maintains Overweight Rating MT
Goldman Sachs Adjusts Price Target on AbbVie to $180 From $173, Keeps Buy Rating MT
BMO Capital Adjusts Price Target on AbbVie to $195 From $187, Maintains Outperform Rating MT
Barclays Adjusts Price Target on AbbVie to $185 From $175, Maintains Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
171.4 USD
Average target price
183.2 USD
Spread / Average Target
+6.93%
High Price Target
207 USD
Spread / Highest target
+20.80%
Low Price Target
168 USD
Spread / Lowest Target
-1.96%

Consensus detail

Consensus revision (last 18 months)

Analysts covering AbbVie Inc.

Piper Sandler
HSBC
Cantor Fitzgerald
Daiwa Securities
BMO Capital
Mizuho Securities
Barclays
Deutsche Bank Securities
UBS
Truist Securities
Morningstar
Wells Fargo Securities
Goldman Sachs
Raymond James
William Blair & Co.
BofA Securities
Morgan Stanley
Guggenheim
Argus
Wolfe Research
Atlantic Equities
SVB Securities LLC
Credit Suisse
Societe Generale
Berenberg Bank
JPMorgan Chase
Cowen
Redburn
SVB Leerink
RBC Capital Markets
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings